Jefferies Financial Group Inc. Sells 6,623 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Jefferies Financial Group Inc. trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,500 shares of the biotechnology company's stock after selling 6,623 shares during the quarter. Jefferies Financial Group Inc. owned 0.07% of Blueprint Medicines worth $4,143,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock worth $3,259,000 after purchasing an additional 265 shares during the last quarter. Empirical Asset Management LLC acquired a new position in Blueprint Medicines during the 4th quarter worth about $2,348,000. SG Americas Securities LLC grew its position in shares of Blueprint Medicines by 69.7% in the 4th quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company's stock valued at $373,000 after buying an additional 1,756 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Blueprint Medicines by 207.5% during the fourth quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company's stock worth $268,000 after acquiring an additional 2,075 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 1,023 shares during the last quarter.

Insider Buying and Selling

In other news, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $101.75, for a total value of $231,379.50. Following the completion of the sale, the chief operating officer now directly owns 66,992 shares of the company's stock, valued at $6,816,436. This represents a 3.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ariel Hurley sold 2,752 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the sale, the insider now directly owns 16,944 shares of the company's stock, valued at approximately $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,503 shares of company stock valued at $1,027,931. 4.21% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BPMC. Piper Sandler increased their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target for the company. JMP Securities restated a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. HC Wainwright restated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. Finally, Needham & Company LLC lowered their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday, April 28th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $126.56.

Blueprint Medicines Stock Up 2.2%

BPMC stock traded up $2.20 during trading on Friday, reaching $101.69. 581,639 shares of the stock were exchanged, compared to its average volume of 778,665. The firm's 50 day moving average is $89.38 and its 200 day moving average is $94.19. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The firm has a market cap of $6.57 billion, a P/E ratio of -94.16 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The firm had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same period last year, the company posted $1.40 earnings per share. The firm's quarterly revenue was up 55.5% compared to the same quarter last year. As a group, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.